Tumor Response

The majority of patients experienced a reduction in tumor size with ENHERTU2

Best percent change from baseline in sum of diameters of target lesions by ICR2,a

A majority of ENHERTU patients experienced more than 30% partial response from baseline; only a small amount saw the progression of disease, 20% over the baseline. A majority of ENHERTU patients experienced more than 30% partial response from baseline; only a small amount saw the progression of disease, 20% over the baseline.
97.3%
DCR
Disease control rate2
DCR=CR+PR+SD
(n=179/184; 95% CI: 93.8, 99.1)
76.1%
CBR
Clinical benefit rate2
CBR=CR+PR+SD≥6 months
(n=140/184; 95% CI: 69.3, 82.1)
  • ENHERTU received accelerated approval from FDA based on tumor response rate and duration of response. FDA has not reviewed these data. Multiple confirmatory Phase 3 studies are underway

aNumbers based on patients treated with ENHERTU 5.4 mg/kg Q3W who had both baseline and postbaseline target lesions assessed by ICR (n=168). For each subject, the minimum (best) percent change from baseline in the sum of the diameters for all target lesions is represented by a vertical line.2

Ready to learn more about ENHERTU?